amifostine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
insecticides, anthelminthics, pesticides etc., phosphorous derivatives	156	20537-88-6

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

amifostine
aminopropylaminoethyl thiophosphate
ethiofos
gammaphos
WR-2721
amifostine trihydrate

A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.

Molecular weight: 214.22
Formula: C5H15N2O3PS
CLOGP: -1.85
LIPINSKI: 0
HAC: 5
HDO: 4
TPSA: 95.58
ALOGS: -1.06
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.70	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.69 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	105 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.09 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	30.65 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.15 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 8, 1995	FDA	CLINIGEN HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pyrexia	45.53	40.14	39	655	380164	50224266

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Mucosal inflammation	131.22	36.10	54	1665	31541	29541267
Laryngeal pain	123.76	36.10	29	1690	2579	29570229
Pyrexia	90.39	36.10	96	1623	287526	29285282
Chills	66.96	36.10	45	1674	71255	29501553
Hypotension	64.49	36.10	67	1652	194287	29378521
Soft tissue disorder	62.59	36.10	13	1706	659	29572149
Rash	55.08	36.10	61	1658	189758	29383050
Dehydration	51.92	36.10	47	1672	114701	29458107
Nausea	47.50	36.10	70	1649	289185	29283623
Dermatitis	45.15	36.10	17	1702	7781	29565027
Injection site reaction	42.51	36.10	18	1701	11170	29561638
Vomiting	41.61	36.10	56	1663	212204	29360604
Radiation skin injury	39.92	36.10	9	1710	671	29572137
Rash maculo-papular	37.22	36.10	21	1698	24268	29548540
Pruritus	36.26	36.10	39	1680	116810	29455998

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Laryngeal pain	150.94	33.39	36	2271	5632	64490793
Mucosal inflammation	117.52	33.39	53	2254	62531	64433894
Pyrexia	110.04	33.39	116	2191	558528	63937897
Hypotension	78.00	33.39	81	2226	380893	64115532
Chills	76.12	33.39	52	2255	137212	64359213
Dehydration	61.00	33.39	55	2252	216708	64279717
Rash	60.87	33.39	78	2229	458471	64037954
Nausea	60.12	33.39	103	2204	785697	63710728
Radiation skin injury	60.02	33.39	13	2294	1317	64495108
Soft tissue disorder	57.95	33.39	15	2292	3261	64493164
Injection site erythema	54.46	33.39	33	2274	70767	64425658
Rash papular	53.95	33.39	21	2286	17092	64479333
Dermatitis	52.88	33.39	21	2286	18008	64478417
Vomiting	51.16	33.39	79	2228	551038	63945387
Injection site reaction	49.97	33.39	27	2280	46637	64449788
Injection site rash	38.17	33.39	16	2291	15726	64480699
Pharyngitis	35.24	33.39	16	2291	19023	64477402

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AF05	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment
CHEBI has role	CHEBI:22586	antioxidants
CHEBI has role	CHEBI:50266	Prodrugs
CHEBI has role	CHEBI:66987	radiation protective drugs
MeSH PA	D020011	Protective Agents
MeSH PA	D011837	Radiation-Protective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Prevention of Xerostomia Secondary to Radiation Therapy	indication
Prevention of Cancer Chemotherapy-Induced Renal Impairment	indication
Myelodysplastic syndrome	off-label use	109995007
Drug-induced mucositis	off-label use	403666006
Chemotherapy-induced neutropenia	off-label use	425229001
Prevention of Chemotherapy-Induced Neurotoxicity	off-label use
Prevention of Radiation Therapy-Induced Mucositis	off-label use
Hypocalcemia	contraindication	5291005
Hypovolemia	contraindication	28560003
Dehydration	contraindication	34095006
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Cerebrovascular accident	contraindication	230690007
Transient ischemic attack	contraindication	266257000	DOID:224
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Vomiting	contraindication	422400008
Nausea	contraindication	422587007

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.67	acidic
pKa2	10.06	Basic
pKa3	8.46	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.18		DRUG MATRIX
Alkaline phosphatase, tissue-nonspecific isozyme	Enzyme	P05186	PPBT_HUMAN					WOMBAT-PK

External reference:

ID	Source
4020970	VUID
N0000148443	NUI
D00226	KEGG_DRUG
1545987	RXNORM
C0015020	UMLSCUI
CHEBI:2636	CHEBI
CHEMBL1006	ChEMBL_ID
DB01143	DRUGBANK_ID
D004999	MESH_DESCRIPTOR_UI
2141	PUBCHEM_CID
M487QF2F4V	UNII
133029	MMSL
4164	MMSL
d03868	MMSL
005536	NDDF
4020970	VANDF
108823002	SNOMEDCT_US
386923005	SNOMEDCT_US
112901-68-5	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ethyol	HUMAN PRESCRIPTION DRUG LABEL	1	76310-017	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	20 sections